Carmen L Wilson1, Tara M Brinkman1,2, Cathleen Cook3, Sujuan Huang4, Geehong Hyun1, Daniel M Green5,6, Wayne L Furman5, Nickhill Bhakta1,7, Matthew J Ehrhardt1,5, Matthew J Krasin8, Leslie L Robison1, Kirsten K Ness1, Melissa M Hudson1,5. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Pediatrics, East Carolina University, Greenville, North Carolina. 4. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 7. Department of Global Health, St. Jude Children's Research Hospital, Memphis, Tennessee. 8. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: The objective of this study was to characterize chronic disease, health-related quality of life (HRQOL), emotional distress, and social attainment among long-term survivors of neuroblastoma. METHODS: Chronic health conditions among 136 ≥10-year neuroblastoma survivors (median age, 31.9 years; range, 20.2-54.6 years) and 272 community controls (median age, 34.7 years; range, 18.3-59.6 years) were graded with a modified version of the Common Terminology Criteria for Adverse Events (version 4.03). HRQOL and emotional distress were assessed with the Medical Outcomes Study 36-Item Short Form Health Survey and the Brief Symptom Inventory-18. Log-binomial regression and logistic regression were used to compare the prevalence of chronic conditions and the frequency of reduced HRQOL, distress, and social attainment between survivors and controls. The cumulative burden approach was used to estimate multimorbidity. RESULTS: By the age of 35 years, survivors had experienced, on average, 8.5 grade 1 to 5 conditions (95% confidence interval [CI], 7.6-9.3), which was higher than the average for controls (3.3; 95% CI, 2.9-3.7). Compared with controls, survivors had a higher prevalence of any pulmonary (P = .003), auditory (P < .001), gastrointestinal (P < .001), neurological (P = .003), or renal condition (P < .001); were more likely to report poor physical HRQOL (P = .01) and symptoms of anxiety (P = .01) and somatization (P = .01); and were less likely to live independently (P = .01) or marry (P = .01). In analyses limited to survivors, those with 1 or more grade 3 to 5 conditions were more likely to report reduced general health (odds ratio [OR], 6.6; 95% CI, 1.6-26.9), greater bodily pain (OR, 4.2; 95% CI, 1.0-17.0), and unemployment (OR, 3.2; 95% CI, 1.2-8.5). CONCLUSIONS: Because of the high burden of chronic diseases and the associations of these morbidities with reduced HRQOL and social attainment, screening and interventions that provide opportunities to optimize health are important among neuroblastoma survivors.
BACKGROUND: The objective of this study was to characterize chronic disease, health-related quality of life (HRQOL), emotional distress, and social attainment among long-term survivors of neuroblastoma. METHODS: Chronic health conditions among 136 ≥10-year neuroblastoma survivors (median age, 31.9 years; range, 20.2-54.6 years) and 272 community controls (median age, 34.7 years; range, 18.3-59.6 years) were graded with a modified version of the Common Terminology Criteria for Adverse Events (version 4.03). HRQOL and emotional distress were assessed with the Medical Outcomes Study 36-Item Short Form Health Survey and the Brief Symptom Inventory-18. Log-binomial regression and logistic regression were used to compare the prevalence of chronic conditions and the frequency of reduced HRQOL, distress, and social attainment between survivors and controls. The cumulative burden approach was used to estimate multimorbidity. RESULTS: By the age of 35 years, survivors had experienced, on average, 8.5 grade 1 to 5 conditions (95% confidence interval [CI], 7.6-9.3), which was higher than the average for controls (3.3; 95% CI, 2.9-3.7). Compared with controls, survivors had a higher prevalence of any pulmonary (P = .003), auditory (P < .001), gastrointestinal (P < .001), neurological (P = .003), or renal condition (P < .001); were more likely to report poor physical HRQOL (P = .01) and symptoms of anxiety (P = .01) and somatization (P = .01); and were less likely to live independently (P = .01) or marry (P = .01). In analyses limited to survivors, those with 1 or more grade 3 to 5 conditions were more likely to report reduced general health (odds ratio [OR], 6.6; 95% CI, 1.6-26.9), greater bodily pain (OR, 4.2; 95% CI, 1.0-17.0), and unemployment (OR, 3.2; 95% CI, 1.2-8.5). CONCLUSIONS: Because of the high burden of chronic diseases and the associations of these morbidities with reduced HRQOL and social attainment, screening and interventions that provide opportunities to optimize health are important among neuroblastoma survivors.
Authors: Caroline Laverdière; Nai-Kong V Cheung; Brian H Kushner; Kim Kramer; Shakeel Modak; Michael P LaQuaglia; Suzanne Wolden; Kirsten K Ness; James G Gurney; Charles A Sklar Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Melissa M Hudson; Kirsten K Ness; Vikki G Nolan; Gregory T Armstrong; Daniel M Green; E Brannon Morris; Sheri L Spunt; Monika L Metzger; Kevin R Krull; James L Klosky; Deo Kumar Srivastava; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2010-12-15 Impact factor: 3.167
Authors: Melissa M Hudson; Matthew J Ehrhardt; Nickhill Bhakta; Malek Baassiri; Hesham Eissa; Wassim Chemaitilly; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Tara M Brinkman; James L Klosky; Kevin R Krull; Noah D Sabin; Carmen L Wilson; I-Chan Huang; Johnnie K Bass; Karen Hale; Sue Kaste; Raja B Khan; Deo Kumar Srivastava; Yutaka Yasui; Vijaya M Joshi; Saumini Srinivasan; Dennis Stokes; Mary Ellen Hoehn; Matthew Wilson; Kirsten K Ness; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: T N Trahair; M R Vowels; K Johnston; R J Cohn; S J Russell; K A Neville; S Carroll; G M Marshall Journal: Bone Marrow Transplant Date: 2007-08-27 Impact factor: 5.483
Authors: Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison Journal: JAMA Date: 2013-06-12 Impact factor: 56.272
Authors: Lillian R Meacham; James G Gurney; Ann C Mertens; Kirsten K Ness; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Date: 2005-04-15 Impact factor: 6.921
Authors: Paul C Nathan; Kirsten K Ness; Mark L Greenberg; Melissa Hudson; Suzanne Wolden; Andrew Davidoff; Caroline Laverdiere; Ann Mertens; John Whitton; Leslie L Robison; Lonnie Zeltzer; James G Gurney Journal: Pediatr Blood Cancer Date: 2007-10-15 Impact factor: 3.838
Authors: Caroline Laverdière; Qi Liu; Yutaka Yasui; Paul C Nathan; James G Gurney; Marilyn Stovall; Lisa R Diller; Nai-Kong Cheung; Suzanne Wolden; Leslie L Robison; Charles A Sklar Journal: J Natl Cancer Inst Date: 2009-07-31 Impact factor: 11.816
Authors: Katie A Devine; Salome Christen; Renée L Mulder; Morven C Brown; Lisa M Ingerski; Luzius Mader; Emma J Potter; Charlotte Sleurs; Adrienne S Viola; Susanna Waern; Louis S Constine; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; Gisela Michel; Jordan Gilleland Marchak; Fiona S M Schulte Journal: Cancer Date: 2022-04-18 Impact factor: 6.921